Pharmacological and non-pharmacological interventions to influence adipose tissue function

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Westerink, Jan ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHNIDONYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ALDOSTERONE ANTAGONIST; ANANDAMIDE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; SALICYLIC ACID; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VALSARTAN; ANTIOBESITY AGENT;

ADIPOSE TISSUE; BARIATRIC SURGERY; BLOOD LEVEL; DIABETES MELLITUS; EXERCISE; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; VASCULAR DISEASE; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; RISK REDUCTION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADIPOSITY; ANTI-OBESITY AGENTS; BARIATRIC SURGERY; CARDIOVASCULAR DISEASES; HUMANS; OBESITY; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 79251538648     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-13     Document Type: Review

References (174)

1. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007, 132:2087-2102. 10.1053/j.gastro.2007.03.052, 17498505.
2. Drolet R, Richard C, Sniderman AD, Mailloux J, Fortier M, Huot C, et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2007,
3. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79. 10.1001/jama.289.1.76, 12503980.
4. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649. 10.1016/S0140-6736(05)67663-5, 16271645.
5. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29:2959-2971. 10.1093/eurheartj/ehn387, 18775919.
6. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273-2282. 10.1210/en.2003-1336, 14726444.
7. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444:860-867. 10.1038/nature05485, 17167474.
8. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808. 296995, 14679176.
9. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200. 10.1210/jc.82.12.4196, 9398739.
10. Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008, 93:1489-1496. 10.1210/jc.2007-1436, 18211973.
11. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-2563. 10.1056/NEJMoa054862, 16775236.
12. Hajer GR, van der Graaf Y, Olijhoek JK, Edlinger M, Visseren FL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J 2007, 154:750-757. 10.1016/j.ahj.2007.07.013, 17893004.
13. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F, Garancini MP, et al. Association between plasma monocyte chemoattractant protein-1 concentration and CVD mortality in middle-aged diabetic and non-diabetic individuals. Diabetes Care 2009, 32:2105-2110. 10.2337/dc09-0763, 2768199, 19641159.
14. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009, 119:1322-1334. 10.1172/JCI37385, 2673878, 19381015.
15. Alzamendi A, Giovambattista A, Raschia A, Madrid V, Gaillard RC, Rebolledo O, et al. Fructose-rich diet-induced abdominal adipose tissue endocrine dysfunction in normal male rats. Endocrine 2009, 35:227-232. 10.1007/s12020-008-9143-1, 19165636.
16. Rebolledo A, Rebolledo OR, Marra CA, Garcia ME, Roldan Palomo AR, Rimorini L, et al. Early alterations in vascular contractility associated to changes in fatty acid composition and oxidative stress markers in perivascular adipose tissue. Cardiovasc Diabetol 2010, 9:65. 10.1186/1475-2840-9-65, 2974659, 20964827.
17. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. 10.1056/NEJMoa012512, 11832527.
18. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007, 30:1374-1383. 10.2337/dc07-0048, 2665929, 17363746.
19. Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993, 153:849-858. 10.1001/archinte.153.7.849, 8466377.
20. Clifton PM, Keogh JB, Foster PR, Noakes M. Effect of weight loss on inflammatory and endothelial markers and FMD using two low-fat diets. Int J Obes (Lond) 2005, 29:1445-1451. 10.1038/sj.ijo.0803039, 16172619.
21. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003, 26:2119-2125. 10.2337/diacare.26.7.2119, 12832323.
22. Keogh JB, Brinkworth GD, Clifton PM. Effects of weight loss on a low-carbohydrate diet on flow-mediated dilatation, adhesion molecules and adiponectin. Br J Nutr 2007, 98:852-859. 10.1017/S0007114507747815, 17490508.
23. Bougoulia M, Triantos A, Koliakos G. Plasma interleukin-6 levels, glutathione peroxidase and isoprostane in obese women before and after weight loss. Association with cardiovascular risk factors. Hormones (Athens ) 2006, 5:192-199.
24. Weinstock RS, Dai H, Wadden TA. Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance. Arch Intern Med 1998, 158:2477-2483. 10.1001/archinte.158.22.2477, 9855386.
25. Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004, 89:2697-2703. 10.1210/jc.2003-031826, 15181044.
26. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357:753-761. 10.1056/NEJMoa066603, 17715409.
27. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007, 298:2028-2037. 10.1001/jama.298.17.2028, 17986696.
28. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504. 10.2337/diacare.23.10.1499, 11023143.
29. Rokling-Andersen MH, Reseland JE, Veierod MB, Anderssen SA, Jacobs DR, Urdal P, et al. Effects of long-term exercise and diet intervention on plasma adipokine concentrations. Am J Clin Nutr 2007, 86:1293-1301.
30. Miller GD, Nicklas BJ, Davis CC, Ambrosius WT, Loeser RF, Messier SP. Is serum leptin related to physical function and is it modifiable through weight loss and exercise in older adults with knee osteoarthritis?. Int J Obes Relat Metab Disord 2004, 28:1383-1390. 10.1038/sj.ijo.0802737, 15278105.
31. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, Loeser RF, et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr 2004, 79:544-551.
32. Weiss EP, Racette SB, Villareal DT, Fontana L, Steger-May K, Schechtman KB, et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr 2006, 84:1033-1042. 1941677, 17093155.
33. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
34. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008, 158:179-187. 10.1530/EJE-07-0721, 18230824.
35. Christiansen T, Paulsen SK, Bruun JM, Ploug T, Pedersen SB, Richelsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010, 95:911-919. 10.1210/jc.2008-2505, 19996310.
36. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199. 10.1136/bmj.39385.413113.25, 2128668, 18006966.
37. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161. 10.2337/diacare.27.1.155, 14693982.
38. Valsamakis G, McTernan PG, Chetty R, Al DN, Field A, Hanif W, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004, 53:430-434. 10.1016/j.metabol.2003.11.022, 15045687.
39. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens ) 2006, 5:259-269.
40. Hsieh CJ, Wang PW, Liu RT, Tung SC, Chien WY, Chen JF, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005, 67:78-83. 10.1016/j.diabres.2004.05.012, 15620437.
41. Lean ME. How does sibutramine work?. Int J Obes Relat Metab Disord 2001, 25(Suppl 4):S8-11.
42. Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, et al. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J Nutr Biochem 2008, 6:371-375.
43. Kim DM, Yoon SJ, Ahn CW, Cha BS, Lim SK, Kim KR, et al. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res Clin Pract 2004, 66(Suppl 1):S139-S144. 10.1016/j.diabres.2003.12.008, 15563965.
44. Ramis JM, Salinas R, Garcia-Sanz JM, Moreiro J, Proenza AM, Llado I. Depot- and gender-related differences in the lipolytic pathway of adipose tissue from severely obese patients. Cell Physiol Biochem 2006, 17:173-180. 10.1159/000092079, 16543734.
45. Phillips CL, Yee BJ, Trenell MI, Magnussen JS, Wang D, Banerjee D, et al. Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. J Clin Sleep Med 2009, 5:416-421. 2762711, 19961024.
46. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010, 363:905-917. 10.1056/NEJMoa1003114, 20818901.
47. Demuth DG, Molleman A. Cannabinoid signalling. Life Sci 2006, 78:549-563. 10.1016/j.lfs.2005.05.055, 16109430.
48. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202. 10.1124/pr.54.2.161, 12037135.
49. Sun Y, Bennett A. Cannabinoids: A New Group of Agonists of PPARs. PPAR Res 2007, 2007:23513. 2220031, 18288264.
50. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007, 152:576-582. 2190029, 17704824.
51. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843. 10.2337/diabetes.54.10.2838, 2228268, 16186383.
52. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008,
53. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134. 10.1056/NEJMoa044537, 16291982.
54. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775. 10.1001/jama.295.7.761, 16478899.
55. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672. 10.1016/S0140-6736(06)69571-8, 17098084.
56. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397. 10.1016/S0140-6736(05)66374-X, 15836887.
57. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008, 57:1140-1155. 10.1136/gut.2008.148791, 18397936.
58. Van GL, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31(Suppl 2):S229-S240.
59. Demaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007, 356:2176-2183. 10.1056/NEJMct067019, 17522401.
60. Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009, 361:445-454. 10.1056/NEJMoa0901836, 2854565, 19641201.
61. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693. 10.1056/NEJMoa035622, 15616203.
62. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752. 10.1056/NEJMoa066254, 17715408.
63. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316-323. 10.1001/jama.299.3.316, 18212316.
64. Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009, 150:94-103.
65. Kim Chung L, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009, 390:613-618. 10.1016/j.bbrc.2009.10.015, 19850014.
66. Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology 2007, 133:1796-1805. 10.1053/j.gastro.2007.09.005, 2185546, 18054552.
67. Lubrano C, Mariani S, Badiali M, Cuzzolaro M, Barbaro G, Migliaccio S, et al. Metabolic or bariatric surgery? Long-term effects of malabsorptive vs restrictive bariatric techniques on body composition and cardiometabolic risk factors. Int J Obes (Lond) 2010, 34:1404-1414. 10.1038/ijo.2010.54, 20404828.
68. Diker D, Vishne T, Maayan R, Weizman A, Vardi P, Dreznik Z, et al. Impact of gastric banding on plasma adiponectin levels. Obes Surg 2006, 16:1057-1061. 10.1381/096089206778026244, 16901360.
69. Gomez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catalan V, Rodriguez A, et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg 2006, 16:262-269. 10.1381/096089206776116525, 16545156.
70. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91:1578-1581. 10.1210/jc.2005-2248, 16449335.
71. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007, 92:1168-1171. 10.1210/jc.2006-1839, 17164313.
72. Schernthaner GH, Kopp HP, Kriwanek S, Krzyzanowska K, Satler M, Koppensteiner R, et al. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. Obes Surg 2006, 16:709-715. 10.1381/096089206777346763, 16756729.
73. van Dielen FM, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 2004, 89:4062-4068. 10.1210/jc.2003-032125, 15292349.
74. Amati F, Dube JJ, Coen PM, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care 2009, 32:1547-1549. 10.2337/dc09-0267, 2713647, 19401446.
75. Nicklas BJ, Wang X, You T, Lyles MF, Demons J, Easter L, et al. Effect of exercise intensity on abdominal fat loss during calorie restriction in overweight and obese postmenopausal women: a randomized, controlled trial. Am J Clin Nutr 2009, 89:1043-1052. 10.3945/ajcn.2008.26938, 2667455, 19211823.
76. Sari R, Balci MK, Balci N, Karayalcin U. Acute effect of exercise on plasma leptin level and insulin resistance in obese women with stable caloric intake. Endocr Res 2007, 32:9-17. 10.1080/07435800701670070, 18271502.
77. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, et al. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil 2007, 14:837-843. 10.1097/HJR.0b013e3282efaf50, 18043308.
78. Lim S, Choi SH, Jeong IK, Kim JH, Moon MK, Park KS, et al. Insulin-sensitizing effects of exercise on adiponectin and retinol-binding protein-4 concentrations in young and middle-aged women. J Clin Endocrinol Metab 2008, 93:2263-2268. 10.1210/jc.2007-2028, 18334592.
79. Simpson KA, Singh MA. Effects of exercise on adiponectin: a systematic review. Obesity (Silver Spring) 2008, 16:241-256. 10.1038/oby.2007.53, 18239630.
80. Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity (Silver Spring) 2009, 17:1150-1157.
81. Hsieh PS, Lu KC, Chiang CF, Chen CH. Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats. Eur J Clin Invest 2010, 40:164-171. 10.1111/j.1365-2362.2009.02239.x, 20039930.
82. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80. 10.1038/23948, 9817203.
83. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005, 201:1205-1215. 10.1084/jem.20041948, 2213148, 15824083.
84. Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. Br Med J 1957, 2:1071-1074. 10.1136/bmj.2.5053.1071, 1962733, 13472052.
85. Hovens MM, Snoep JD, Groeneveld Y, Frolich M, Tamsma JT, Huisman MV. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes Obes Metab 2008, 8:668-674.
86. Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009, 52:385-393. 10.1007/s00125-008-1239-x, 2989538, 19104769.
87. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes. Clin Transl Sci 2008, 1:36-43. 10.1111/j.1752-8062.2008.00026.x, 2662587, 19337387.
88. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912. 10.1056/NEJM200003303421301, 10738048.
89. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989, 298:1152-1157. 10.1136/bmj.298.6681.1152, 1836369, 2500169.
90. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007, 120:10-27. 10.1016/j.ijcard.2007.01.069, 17433471.
91. Sawicki PT, Siebenhofer A. Betablocker treatment in diabetes mellitus. J Intern Med 2001, 250:11-17. 10.1046/j.1365-2796.2001.00829.x, 11454137.
92. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 2001, 37:250-254.
93. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001, 507:142-146. 10.1016/S0014-5793(01)02960-X, 11684087.
94. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006, 24:591-596. 10.1097/01.hjh.0000209993.26057.de, 16467663.
95. Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group. Cardiovasc Drugs Ther 2000, 14:67-75. 10.1023/A:1007847306219, 10755203.
96. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett 2004, 91:87-91. 10.1016/j.imlet.2003.11.008, 15019274.
97. Lamounier-Zepter V, Ehrhart-Bornstein M. Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep 2006, 8:30-34. 10.1007/s11906-006-0038-3, 16600157.
98. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185-2194. 10.1096/fj.06-7970com, 17384139.
99. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253-2261. 10.1161/CIRCULATIONAHA.107.748640, 2746647, 18427128.
100. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009, 84:164-172. 10.1093/cvr/cvp191, 19505930.
101. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006, 55:1645-1652. 10.1016/j.metabol.2006.07.025, 17142138.
102. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153. 10.1056/NEJM200001203420301, 10639539.
103. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al. Ramipril and the development of diabetes. JAMA 2001, 286:1882-1885. 10.1001/jama.286.15.1882, 11597291.
104. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, et al. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 2009, 58:708-713. 10.1016/j.metabol.2009.01.013, 19375596.
105. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100:2158-2169. 10.1172/JCI119752, 508410, 9410892.
106. Skurk T, van H V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler Thromb Vasc Biol 2004, 24:1199-1203. 10.1161/01.ATV.0000131266.38312.2e, 15130920.
107. Skurk T, van H V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 2005, 13:969-973. 10.1038/oby.2005.113, 15976138.
108. Tsuchiya K, Yoshimoto T, Hirono Y, Tateno T, Sugiyama T, Hirata Y. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006, 291:E771-E778. 10.1152/ajpendo.00560.2005, 16705055.
109. Mathai ML, Naik S, Sinclair AJ, Weisinger HS, Weisinger RS. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) 2008, 32:1576-1584. 10.1038/ijo.2008.126, 18698317.
110. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A, et al. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008, 38:820-826. 10.1111/j.1365-2362.2008.02025.x, 19021699.
111. Delles C, Raff U, Mimran A, Fauvel JP, Ruilope LM, Schmieder RE. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008, 21:1330-1336. 10.1038/ajh.2008.297, 18989258.
112. Nakamura T, Kawachi K, Saito Y, Saito T, Morishita K, Hoshino J, et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J 2009, 50:501-512. 10.1536/ihj.50.501, 19609054.
113. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton ) 2007, 12:147-153. 10.1111/j.1440-1797.2007.00764.x, 17371337.
114. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006, 24:1405-1412. 10.1097/01.hjh.0000234122.55895.5b, 16794491.
115. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006, 55:1159-1164. 10.1016/j.metabol.2006.04.013, 16919533.
116. Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, Yamazaki Y, et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007, 77:210-214. 10.1016/j.diabres.2006.11.014, 17240472.
117. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 2006, 24:1809-1816. 10.1097/01.hjh.0000242405.68461.84, 16915030.
118. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057. 10.1161/01.CIR.0000127955.36250.65, 15117841.
119. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46:137-143. 10.1161/01.HYP.0000168046.19884.6a, 15939809.
120. Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, Ohnishi A, et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 2007, 30:1205-1210. 10.1291/hypres.30.1205, 18344626.
121. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007, 25:841-848. 10.1097/HJH.0b013e3280287a83, 17351377.
122. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006, 29:849-856. 10.1291/hypres.29.849, 17345784.
123. Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H, et al. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension 2009, 53:798-804. 10.1161/HYPERTENSIONAHA.108.126656, 19289654.
124. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42:76-81. 10.1161/01.HYP.0000078490.59735.6E, 12796280.
125. Abe M, Matsuda M, Kobayashi H, Miyata Y, Nakayama Y, Komuro R, et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 2008, 28:871-877. 10.1161/ATVBAHA.107.160663, 18323514.
126. Desjardins F, Sekkali B, Verreth W, Pelat M, De KD, Mertens A, et al. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 2008, 29:128-137. 10.1093/eurheartj/ehm540, 18063594.
127. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. 10.1056/NEJMoa0807646, 18997196.
128. Takagi T, Matsuda M, Abe M, Kobayashi H, Fukuhara A, Komuro R, et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008, 196:114-121. 10.1016/j.atherosclerosis.2007.02.013, 17391675.
129. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105. 10.1016/j.pharmthera.2006.03.003, 16714062.
130. Gannage-Yared MH, Azar RR, mm-Azar M, Khalife S, Germanos-Haddad M, Neemtallah R, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005, 54:947-951. 10.1016/j.metabol.2005.02.011, 15988706.
131. Sakamoto K, Sakamoto T, Ogawa H. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 2006, 28:1012-1021. 10.1016/j.clinthera.2006.07.001, 16990079.
132. Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-e51. 10.1016/j.atherosclerosis.2006.08.023, 17112529.
133. Blanco-Colio LM, Martin-Ventura JL, Gomez-Guerrero C, Masramon X, de TE, Farsang C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 2008, 586:259-265. 10.1016/j.ejphar.2008.02.042, 18374327.
134. Ichida Y, Hasegawa G, Fukui M, Obayashi H, Ohta M, Fujinami A, et al. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology 2006, 76:34-39. 10.1159/000088948, 16227702.
135. Miyagishima K, Hiramitsu S, Kato S, Kato Y, Kitagawa F, Teradaira R, et al. Efficacy of atorvastatin therapy in ischaemic heart disease - effects on oxidized low-density lipoprotein and adiponectin. J Int Med Res 2007, 35:534-539.
136. Otto C, Otto B, Frost RJ, Vogeser M, Pfeiffer AF, Spranger J, et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007, 44:65-68. 10.1007/s00592-007-0244-8, 17530469.
137. Devaraj S, Siegel D, Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol 2007, 100:1397-1399. 10.1016/j.amjcard.2007.06.028, 2080663, 17950796.
138. Forst T, Pfutzner A, Lubben G, Weber M, Marx N, Karagiannis E, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. Metabolism 2007, 56:491-496. 10.1016/j.metabol.2006.11.007, 17379006.
139. Pfutzner A, Hanefeld M, Lubben G, Weber MM, Karagiannis E, Kohler C, et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study. Horm Metab Res 2007, 39:764-768. 10.1055/s-2007-985867, 17952841.
140. Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008, 578:249-252. 10.1016/j.ejphar.2007.09.019, 17931620.
141. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
142. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929. 10.2337/dc09-0738, 2752935, 19794004.
143. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de CA, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742. 10.1016/S0140-6736(09)61965-6, 20167359.
144. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038. 10.1093/eurheartj/ehi310, 15872029.
145. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007, 27:635-641. 10.1161/01.ATV.0000256469.06782.d5, 17194889.
146. Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008, 28:1050-1059. 10.1161/ATVBAHA.107.158998, 18323516.
147. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14. 10.1186/1475-2840-4-14, 1236941, 16168052.
148. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11:779-791. 10.1210/me.11.6.779, 9171241.
149. Zirlik A, Ernst S, Leugers A, Willecke F, Sobel BE, Bode C, et al. Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes. Thromb Haemost 2009, 101:1060-1069.
150. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005, 336:747-753. 10.1016/j.bbrc.2005.08.203, 16157299.
151. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006, 91:1770-1778. 10.1210/jc.2005-1615, 16492702.
152. Wu H, Wei L, Bao Y, Lu J, Huang P, Liu Y, et al. Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. Am J Physiol Endocrinol Metab 2009, 296:E628-E634. 10.1152/ajpendo.90526.2008, 19088257.
153. Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J 2007, 54:431-435. 10.1507/endocrj.K06-172, 17457016.
154. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105. 10.1016/S0140-6736(06)69829-2, 16997664.
155. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784-2791. 10.1210/jc.87.6.2784, 12050251.
156. Aso Y, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Matsutomo R, et al. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes. Diabet Med 2007, 24:962-968. 10.1111/j.1464-5491.2007.02204.x, 17509067.
157. Lin KD, Chang YH, Wang CL, Yang YH, Hsiao PJ, Li TH, et al. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea. Transl Res 2008, 151:309-314. 10.1016/j.trsl.2008.04.003, 18514142.
158. Ikeda Y, Osaki F, Maruyama H, Inada S, Shinahara M, Inoue K, et al. The Effect of pioglitazone on circulating adiponectin is highly predictable based on its basal level. Diabetes Res Clin Pract 2008, 80:e12-e13. 10.1016/j.diabres.2008.01.026, 18355937.
159. Kim HJ, Kim SK, Shim WS, Lee JH, Hur KY, Kang ES, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 81:42-49. 10.1016/j.diabres.2008.02.001, 18394743.
160. van H V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998, 47:913-917. 10.2337/diabetes.47.6.913, 9604868.
161. Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, Tse HF, et al. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler Thromb Vasc Biol 2007, 27:2777-2782. 10.1161/ATVBAHA.107.152462, 17932317.
162. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007, 49:1772-1780. 10.1016/j.jacc.2006.12.048, 17466227.
163. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135. 10.1016/S0140-6736(09)60953-3, 19501900.
164. Nissen SE, Wolski K. Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med 2010, 14:170.
165. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135. 10.1016/S0140-6736(09)60870-9, 19515415.
166. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. 10.1056/NEJMoa012512, 1370926, 11832527.
167. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006, 26:611-617. 10.1161/01.ATV.0000201938.78044.75, 16385087.
168. Bourron O, Daval M, Hainault I, Hajduch E, Servant JM, Gautier JF, et al. Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase. Diabetologia 2010, 53:768-778. 10.1007/s00125-009-1639-6, 20043143.
169. He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. Horm Metab Res 2003, 35:18-23. 10.1055/s-2003-38386, 12669266.
170. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003, 52:667-674. 10.2337/diabetes.52.3.667, 12606507.
171. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004, 89:5043-5047. 10.1210/jc.2004-0436, 15472203.
172. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008, 57:1501-1507. 10.2337/db08-0127, 18375437.
173. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin Treatment May Increase Omentin-1 Levels in Women with Polycystic Ovary Syndrome. Diabetes 2010,
174. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006, 91:2074-2080. 10.1210/jc.2006-0241, 16595599.